Fuhong Dai1, Jiangye Wang1, Hongshan An2, Ting Lei3, Ke Tang4, Xiaochun Ma5, Peng Duo6, Pengyun Ren7, Wenxiao Chai1. 1. Department of Interventional Oncology, Gansu Provincial Hospital Lanzhou, Gansu, China. 2. Department of Interventional Therapy, Tianzhu County People's Hospital Tianzhu, Gansu, China. 3. Department of Reproductive Center, Minle County Maternity and Child-Care Hospital Minle, Gansu, China. 4. Department of Medical Imaging, Linxia State Hospital Linxia, Gansu, China. 5. Department of Radiotherapy, Gansu Provincial Hospital Lanzhou, Gansu, China. 6. Second Department of Surgery, Minle County Chinese Medicine Hospital Minle, Gansu, China. 7. Department of Interventional Therapy, Minle County Chinese Medicine Hospital Minle, Gansu, China.
Abstract
BACKGROUND: The aim of this study was to investigate the efficacy and safety of 125I particle implantation for treating advanced non-small cell lung cancer (NSCLC). METHODS: Data from 56 patients with advanced NSCLC between January 2013 and May 2016 were retrospectively analyzed. The changes of tumor size, objective response rate (ORR), disease control rate (DCR), survival rate of patients and occurrence rate of complications were calculated, and the levels of carcinoembryonic antigen (CEA) and cytokerantin-19-fragment (CYFRA21-1) before and after the treatment were evaluated. RESULTS: The 125I particles implantation therapy significantly inhibited the tumor local growth of NSCLC (from 7.75±6.69 to 3.39±2.12 cm) (P<0.001), suggesting a better effectiveness with an RR of 55.4% and DCR of 98.2%. In addition, the 125I particle implantation down-regulated the CEA expression level of lung adenocarcinoma (LAC) patients (P<0.05). The one-year, two-year, three-year survival rate were 41.1%, 39.3% and 19.6% respectively after the implantation therapy. However, patients implanted 125I particles had no serious complications except for slight fever. CONCLUSIONS: NSCLC patients at different clinical features all can benefit from the 125I particle implantation therapy. Moreover, the level of CEA can be used as an efficacy predictor for the 125I particle implantation therapy for LAC.
BACKGROUND: The aim of this study was to investigate the efficacy and safety of 125I particle implantation for treating advanced non-small cell lung cancer (NSCLC). METHODS: Data from 56 patients with advanced NSCLC between January 2013 and May 2016 were retrospectively analyzed. The changes of tumor size, objective response rate (ORR), disease control rate (DCR), survival rate of patients and occurrence rate of complications were calculated, and the levels of carcinoembryonic antigen (CEA) and cytokerantin-19-fragment (CYFRA21-1) before and after the treatment were evaluated. RESULTS: The 125I particles implantation therapy significantly inhibited the tumor local growth of NSCLC (from 7.75±6.69 to 3.39±2.12 cm) (P<0.001), suggesting a better effectiveness with an RR of 55.4% and DCR of 98.2%. In addition, the 125I particle implantation down-regulated the CEA expression level of lung adenocarcinoma (LAC) patients (P<0.05). The one-year, two-year, three-year survival rate were 41.1%, 39.3% and 19.6% respectively after the implantation therapy. However, patients implanted 125I particles had no serious complications except for slight fever. CONCLUSIONS:NSCLCpatients at different clinical features all can benefit from the 125I particle implantation therapy. Moreover, the level of CEA can be used as an efficacy predictor for the 125I particle implantation therapy for LAC.